



## Solenio Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference

November 22, 2017

REDWOOD CITY, Calif., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Solenio Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Piper Jaffray 29th Annual Healthcare Conference, taking place November 28-29 in New York City.

### **Presentation Details:**

Date: Wednesday, November 29

Time: 12:00pm Eastern Time

Location: Lotte New York Palace Hotel, Track 4, Holmes 2 Ballroom

### **About Solenio Therapeutics, Inc.**

Solenio Therapeutics, Inc. (Solenio) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program in early 2018. Solenio, through its wholly-owned subsidiary, Capnia, Inc., continues to market Capnia's innovative medical device, the CoSense® End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. It is expected that CoSense will be monetized and will not be a focus for the company in the long-term.

For more information, please visit [www.solenio.life](http://www.solenio.life).

### CONTACT:

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578

 [Primary Logo](#)

Source: Solenio Therapeutics